Back to results
US 2019/0290759 A1Published application
Combination of hdac inhibitor and anti-pd-l1 antibody for treatment of ovarian cancer
AssigneesSyndax Pharmaceuticals, Inc., Merck Patent GmbH
InventorsPeter Ordentlich, Michael Meyers
Life of this patent
Estimating the term…
Abstract
Described herein are methods for the treatment of heavily pre-treated recurrent ovarian cancer. In particular, methods are provided for the treatment of heavily pre-treated recurrent ovarian cancer with a combination of entinostat and an anti-PD-L1 antibody.
Claims24
A method of treating cancer, comprising administering to a patient a combination comprising entinostat and an anti-PD-L1 antibody, wherein the cancer is ovarian cancer.
(canceled)
A kit for treating heavily pre-treated recurrent ovarian cancer comprising a combination of entinostat and an anti-PD-L1 antibody.
Dependencies are inferred from the claim text.